As Nxera Pharma proceeds into the “next era” implied by its name—following a rebrand from Sosei Group last year—the Japanese drugmaker is adding a new executive to help guide its growth plans. Kiyoshi ...
Total dividend declared for FY 2025 increased by 3% to $3.20 per share 16 positive Phase 3 readouts and 43 approvals in major regions in the last twelve months Pascal Soriot, Chief Executive Officer, ...
As President Donald Trump’s tariff policies loom, global pharmaceutical giant AstraZeneca will invest $50 billion to boost its American manufacturing and R&D infrastructure. Chief among the company’s ...
AstraZeneca's net profit jumped 45% in 2025, driven by strong cancer drug sales and expansion into the US and China markets, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results